Shows
The HemOnc PulseNavigating Drug Accessibility in Cancer Care
In this episode of The Hem Onc Pulse, Dr. Rahul Banerjee is joined by Dr. Michelle Longmire, CEO and co-founder of Medable, for a compelling discussion on drug accessibility in cancer care. Together, they explore how decentralized clinical trials and digital tools can help bridge the gap between cutting-edge therapies and the patients who need them most. Dr. Longmire shares how Medable is expanding access to clinical research, particularly in rural and underserved communities, by reimagining how trials are conducted.
The conversation also examines the systemic and financial challenges that often prevent patients from accessing approved cancer...2025-06-2016 minThe HemOnc PulseThe 'HemOnc Pulse Live' Controversies in Aggressive NHLIn this HemOnc Pulse Live! edition of podcast, Dr. Mehdi Hamadani leads a comprehensive panel discussion on controversies and unanswered questions in the treatment of aggressive non-Hodgkin lymphoma. Dr. Hamadani is joined by Drs. Timothy Fenske, Madiha Iqbal, Urshila Durani, and Mohamed Kharfan-Dabaja.
2025-06-0512h 10The HemOnc PulseInside the War on Myeloid Malignancies: Early Clues & Bold Innovations
In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology’s hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn’t just helpful—it’s lifesaving.
2025-05-2320 minThe HemOnc Pulse'The HemOnc Pulse' Live 2025: Controversies in MDSIn this special episode of our podcast, recorded live at HemOnc Pulse Live in Austin, Texas on May 2–3, 2025, leading experts tackle some of the most pressing controversies in the management of myelodysplastic syndromes. Moderated by Naval Daver, MD, this dynamic panel discussion brings together top thought leaders in hematologic malignancies to debate evolving treatment standards, diagnostic challenges, and the integration of emerging therapies in clinical practice.
2025-05-0930 minThe HemOnc PulseRedirected Strategy: Tal and TEC in the Myeloma MixIn this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial’s rationale, design, and real-world implications for patients with relapsed or refractory disease.
Tune in to hear expert perspectives on unmet needs in late-line myeloma car...2025-05-0216 min
ASTCT TalksKey CAR T and Transplantation Presentations From The 2025 Tandem MeetingCancerNetwork®, in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT)®, hosted a Twitter/X Space during the 2025 Tandem Meetings. The live conversation featured Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, and Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center. Together, they shared expert commentary on new data in CAR T-cell therapy and hematopoietic cell transplantation.With insights drawn from posters, oral abstracts, and late-breaking presentations, the session unpacked both clinical takeaways and implications for patient care.Highlights included:LBA1 – Ide-cel + lenalidomide maintenance post-transplant in MM patients“This m...2025-04-2456 min
Oncology Data AdvisorAdditional Advances in Relapsed/Refractory Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACPThe fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical.
In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no...2025-04-0448 min
i3 Health PodcastAdditional Advances in Relapsed/Refractory Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACPThe fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical.
In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no...2025-04-0448 min
Oncology On The GoKey CAR T and Transplantation Presentations From The 2025 Tandem MeetingCancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.
The conversation took place during the 2025 Tandem Meeting and highlighted many significant presentations and posters on CAR T-cell therapies and transplantation, Banerjee’s and Holtan’s respective areas of expertise.
The following trials were discussed:
LBA1 - Phas...2025-03-0356 minThe HemOnc PulseDr. Usmani Highlights Myeloma Presentations from SOHO 2024On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-11-2025 minThe HemOnc PulseCovering MDS Updates at SOHO 2024 With Dr. VenugopalOn this episode of "The HemOnc Pulse," Chadi Nabhan, MD, MBA, FACP, is joined by Sangeetha Venugopal, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, to highlight data on myelodysplastic syndromes (MDS) presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-11-0125 minThe HemOnc PulseAML News From SOHO 2024 With Dr. DaverOn this episode of "The HemOnc Pulse," Naval Daver, MD, of the MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss news on acute myeloid leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-10-1123 minThe HemOnc PulseDr. Shadman Shares SOHO 2024 Data On CLLOn this episode of "The HemOnc Pulse," Mazyar Shadman, MD, MPH, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to highlight some of the notable presentations on chronic lymphocytic leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-09-2729 min
Couchonomics with ArjunEp 95. Transforming Access And Trading Bonds To A New Era With Rahul BanerjeeIn this episode of Couchonomics with Arjun, we're joined by Rahul Banerjee, Founder & CEO of Bondblox, to explore the future of bond trading. Rahul shares how Bondblox is transforming access to bonds, opening up opportunities for retail investors in a market traditionally controlled by institutions.Arjun and Rahul discuss the rapid growth of the bond market, particularly in Asia, and how technology is playing a key role in bridging the gap between institutional and individual investors. If you're curious about the bond market's impact on your wealth or interested in the latest financial innovations, this conversation is...2024-09-2451 minThe HemOnc PulseDr. Bose on MPN Highlights From SOHO 2024On this episode of "The HemOnc Pulse," Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss some of the important data on myeloproliferative neoplasms that were presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-09-1726 min
The NEWS With NDTVThe NEWS Ep124: Mamata Banerjee To Meet Doctors, BJP Attacks Rahul Gandhi, Trump Vs Harris DebateIn today's episode, protesting doctors to meet Bengal Chief Minister Mamata Banerjee, BJP attacks Rahul Gandhi over his comments in US on reservation and RSS, Arvind Kejriwal custody extended, and Kamala Harris vs Donald Trump debate ahead of the US presidential election.2024-09-1110 minThe HemOnc PulsePart Two: The Question of MRD in CLL TherapyIn part two of this episode, Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health, continue to explore the role of measurable residual disease (MRD) in the treatment of patients with chronic lymphocytic leukemia (CLL).
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies.
2024-08-2220 minThe HemOnc PulseDr. Osman on Identifying and Treating High-Risk MDSOn “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.
2024-08-0925 minThe HemOnc PulseDr. Rami Komrokji on Trends in Real-World MDS CareOn “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center is home to a large MDS database, with clinical information on nearly 6,000 patients, a trove of real-world MDS data.
2024-07-2528 minThe HemOnc PulsePart One: The Question of MRD in CLL TherapyPart one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health.
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies.
2024-07-1835 minThe HemOnc Pulse‘The HemOnc Pulse’ Live: Unanswered Questions in T-Cell LymphomaAt the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management. The panelists were Mehdi Hamadani, MD, a Professor of Internal Medicine at the Medical College of Wisconsin, Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services at Rutgers Cancer Center, and Barbara Pro, MD, a Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
2024-05-3032 minThe HemOnc Pulse‘The HemOnc Pulse’ Live 2024: Is it Time for New Endpoints in MPN?Recorded at the first annual “HemOnc Pulse” Live meeting, this episode features a panel discussion on unanswered questions in myeloproliferative neoplasms (MPN) with Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center; Ruben Mesa, MD, of the Atrium Health cancer service line; Sanam Loghavi, MD, of the MD Anderson Cancer Center; and Olatoyosi Odenike, MD, of the University of Chicago Medicine.
2024-05-2951 minThe HemOnc PulseUnpacking Bispecifics at ‘The HemOnc Pulse’ Live Meeting“The HemOnc Pulse” was live for the first time in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in a range of hematologic malignancies. As part of the program, Michael Bishop MD, of the University of Chicago, and Aaron Goodman, MD, of the University of California, San Diego, were joined by Rafael Fonseca, MD, of the Mayo Clinic, to hold a panel on bispecific therapies and explore unanswered questions related to them.
2024-05-2446 minThe HemOnc Pulse'The HemOnc Pulse' Live: Unanswered Questions in Treating DLBCLIn this podcast episode covering the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in managing diffuse large B-cell lymphoma. The panelists included Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic; Jane Winter, MD, a Professor of Medicine in the Division of Hematology and Oncology at the Northwestern University Feinberg School of Medicine; and Alan Skarbnik, MD, Director of the Lymphoma and Chronic Lymphocytic Leukemia Program and of Experimental Therapeutics, Malignant Hematology at Novant Health.
2024-05-2332 minThe HemOnc Pulse‘The HemOnc Pulse’ Live 2024: Unanswered Questions in CML TreatmentRecorded at the first “HemOnc Pulse” Live meeting in Chicago, this podcast episode features a panel discussion on unanswered questions in chronic myeloid leukemia (CML) with Elias Jabbour, MD, a Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the University of Miami Sylvester Comprehensive Cancer Center; and Sangeetha Venugopal, MD, MS, an Assistant Professor of Medicine at the Sylvester Comprehensive Cancer Center.
2024-05-2128 minThe HemOnc Pulse‘The HemOnc Pulse’ Live: What Are the Unanswered Questions in ALL?Recorded at the first “HemOnc Pulse” annual meeting, this podcast episode features a panel discussion on unanswered questions in acute lymphoblastic leukemia (ALL) with Elias Jabbour, MD, a Professor of Medicine at the University of Texas MD Anderson Cancer Center; Shira Dinner, MD, an Associate Professor of Medicine (Hematology and Oncology) at Northwestern Medicine; Sanam Loghavi, MD, an Associate Professor of Pathology at MD Anderson Cancer Center; and Wendy Stock, MD, Co-Leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center.
2024-05-2132 minThe HemOnc PulseDiscussing the Role of MRD in CLL With Talal Hilal, MDDr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).
2024-05-1621 minThe HemOnc Pulse‘The HemOnc Pulse’ Live 2024: How Is Hodgkin Lymphoma Treated?Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in Hodgkin lymphoma with Andrew Evens, DO, MBA, MSc, Director of the Lymphoma Program and Associate Director of Rutgers Cancer Institute; Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in Division of Hematology at the Mayo Clinic; and Jane Winter, MD, a Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine.
2024-05-1425 minThe HemOnc PulseUnanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in ChicagoRecorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in myelodysplastic syndromes (MDS) with Rami Komrokji, MD, Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center; Sanam Loghavi, MD, an Associate Professor of Pathology at the University of Texas MD Anderson Cancer Center; Jamile Shammo, MD, FACP, FASCP, a Professor at the Northwestern University Feinberg School of Medicine; Sangeetha Venugopal, MD, MS, an Assistant Professor of Medicine at the University of Miami Sylvester Comprehensive Cancer Center; and Amer Zeidan, MBBS, MHS, an Associate Professor of Medicine at Yale University.
2024-05-1331 minThe HemOnc Pulse‘The HemOnc Pulse Live’ in Chicago: Fellows Discuss Choosing a Career Path in Hematology OncologyThis podcast episode features a panel discussion on challenges and opportunities for hematology oncology fellows with Megan Melody, MD, a third-year fellow at Northwestern University; Alexandra Rojek, MD, a second-year fellow at the University of Chicago Medicine Comprehensive Care Center; Seda Tolu, MD, a third-year fellow at the Columbia University Herbert Irving Comprehensive Cancer Center; Zaker Schwabkey, MD, a third-year fellow at Moffit Cancer Center; Himachandana Atluri, MD, a third-year fellow at the University of Texas MD Anderson Cancer Center; and Hannah Goulart, MD, a first-year fellow at MD Anderson Cancer Center.
2024-05-0839 min
i3 Health PodcastAdditional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACPDr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for pa...2024-05-0705 minThe HemOnc Pulse“The HemOnc Pulse” Live 2024 in Chicago: CAR-T Unanswered Questions“The HemOnc Pulse” goes on the road to Chicago May 3-4 with host Chadi Nabhan, MD, MBA, FACP, for the first live meeting.
This podcast episode features a panel discussion on unanswered questions in chimeric antigen receptor (CAR) T-cell therapy with Caron Jacobson, MD, MMSc, Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute; Michael Bishop, MD, FACP, FASCO, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago; Joseph Mikhael, MD, MEd, FRCPC, FACP, a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Research Inst...2024-05-0538 minThe HemOnc Pulse"The HemOnc Pulse" Live 2024 in Chicago: AML Unanswered Questions"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP.
This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida; and Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the Sylvester...2024-05-0434 min
Oncology Data AdvisorAdditional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACPDr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for pa...2024-05-0305 minThe HemOnc PulseWhat are the Controversies Surrounding MRD in Blood Cancers?On this episode of "The HemOnc Pulse," Alan Skarbnik, MD, of Novant Health, and Manni Mohyuddin, MBBS, of the University of Utah, discuss the concept of measurable residual disease (MRD) in hematologic malignancies and highlight the polarized views surrounding MRD.
They also weigh the implications of MRD negativity, how to harmonize the MRD threshold, and how trials are putting MRD technology to the test.
2024-04-2540 minThe HemOnc PulseHMAs Are ‘Cornerstone’ of High-Risk MDS Treatment, Says Jamile Shammo, MDOn this episode of “The HemOnc Pulse,” Dr. Shammo, a Professor of Medicine in Hematology and Oncology at Northwestern Medicine, discusses how to approach treatment for myelodysplastic syndromes (MDS).
Dr. Shammo speaks on everything from low- to high-risk treatment of patients with MDS, including why hypomethylating agents are the cornerstone for treating high-risk patients with MDS.
2024-04-1027 minThe HemOnc PulseKrish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCLDr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.
2024-04-0422 minThe HemOnc PulseAaron Goodman, MD, Tells Us the 'Crux' of Castleman DiseaseIn this episode of "The HemOnc Pulse," Dr. Goodman, an Associate Professor of Medicine at the University of California San Diego, joins Chadi Nabhan, MD, MBA, FACP, to discuss Castleman Disease.
Dr. Goodman explains why the rare disease is often mismanaged, how each subtype is diagnosed and treated, and how it's comparable to hematologic cancers like lymphoma or myeloma.
2024-04-0226 minThe HemOnc PulseIs MRD Negativity the New Benchmark in ALL Treatment Strategies?Elias Jabbour, MD, an Executive Editor of Blood Cancers Today and a Professor of Leukemia at the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the function of measurable residual disease in treating acute lymphocytic leukemia (ALL) and other progress that has been made in treating patients with Philadelphia chromosome-positive and Philadelphia chromosome-negative ALL.
Dr. Jabbour also provides a brief historical perspective on tyrosine kinase inhibitors (TKIs), explaining how the therapies have improved survival outcomes in Ph+ ALL with or without transplantation.
2024-03-1419 minThe HemOnc PulsePart Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T TherapiesSaurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, join The HemOnc Pulse for the second half of a two-part series on reports regarding secondary T-cell malignancies in patients after being treated with a chimeric antigen receptor (CAR) T-cell therapy and updates from the US Food and Drug Administration (FDA) on the issue.
Drs. Dahiya and Spiegel return to the show shortly following the announcement that the FDA sent requests to drug manufacturers on January 9 to update prescription labels with "Black Box" warnings on the six CAR-T therapies used to...2024-02-2932 minThe HemOnc PulseDr. Coombs Spotlights Recent CHIP UpdatesIn this season's fourth episode of "The HemOnc Pulse," Catherine Coombs, MD, an Associate Professor in the Division of Hematology/Oncology at the University of California, Irvine, School of Medicine, highlights recent studies in clonal hematopoiesis of indeterminate potential (CHIP) presented at the 65th American Society of Hematology Meeting & Exposition.
Dr. Coombs discusses research on reversing the adverse effects of CHIP, particularly its association with atherosclerotic cardiovascular disease, using interventions such as selective nuclear export inhibitors. She also illustrates another study that looks at the prevalence of CHIP in patients undergoing autologous hematopoietic stem cell transplant in l...2024-02-1529 minThe HemOnc PulseDrs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk
An all-new episode of The HemOnc Pulse with Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, features a discussion on the link between chimeric antigen receptor (CAR)-T cell therapies and secondary T-cell malignancies. The episode follows on the heels of the US Food and Drug Administration's request to drug manufacturers of the six CAR-T therapies to make safety-related labeling changes.
2024-02-0840 min
The Garima Avtar ShowHow to transform habits for peak performance? Ft. Rahul bannerjee, Archer Arjuna Awardee Ep 86In this episode, Rahul Banerjee, Archer Arjuna Awardee stresses that success is not just an end result but an ongoing process, achieved through hard work and dedication. He encourages aspiring athletes to see sports as a viable career rather than just a hobby. Using the analogy of planting seeds and nurturing them, he highlights the significance of persistence in achieving success. Banerjee outlines the daily habits of a champion, including early wake-ups, meditation, training, and proper nutrition. He also talks about the importance of patience and maintaining a positive attitude while working towards goals. The idea of mastering skills...2024-01-2719 min
The HemOnc PulseAditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDSThis episode features a conversation between Dr. Shastri, an Assistant Professor of Medicine at the Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, and The HemOnc Pulse host, Chadi Nabhan; MD; MBA; FACP; on the latest news in myelodysplastic syndromes (MDS), including the final readout from the COMMANDS trial and the clinical implications of TP53-mutated MDS.2024-01-1823 min
The HemOnc PulseWhat It Takes to Harmonize the World’s Hodgkin Lymphoma DataThe first episode of The HemOnc Pulse of the new year features an in-depth discussion by the leading researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium.
Principal investigators Susan Parsons, MD, MRP; and Andrew Evans, DO, MBA, MSc; are joined by Matthew Maurer, DMSc; to share the story behind harmonizing the world's Hodgkin lymphoma data, and what the effort means for both clinicians and patients.2024-01-0440 min
The HemOnc PulseDr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma UpdatesSaad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in multiple myeloma from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing in the hematologic oncology space. He also reflects on the Perseus and IsKia trials, which were presented at ASH 2023.2023-12-1827 min
The HemOnc PulseDr. Venugopal Offers Her Thoughts on the Latest MDS NewsSangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the COMMANDS trial, and if she believes MDS is a distinct disease.
She also highlights the latest research in MDS at the 65th American Society of Hematology Annual Meeting and Exposition.2023-12-1828 min
The HemOnc PulseJerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023In this episode of The HemOnc Pulse, Jerald Radich, MD, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss various abstracts on acute myeloid leukemia (AML) presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. The conversation centered around menin inhibitors for the treatment of AML, the effect of measurable residual disease-positivity on transplantation outcomes, and whether age plays a role in transplantation.2023-12-1736 min
The HemOnc PulseInside the FDA ODAC ’Yes’ Vote to PolivyIn this episode of The HemOnc Pulse, Grzegorz Nowakowski MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, recounts his experience serving on the FDA Oncologic Drugs Advisory Committee that reviewed and evaluated data from the POLARIX study and polatuzumab vedotin-piiq (Polivy)for patients with previously untreated LBCL.2023-11-3031 min
The HemOnc PulseKami Maddocks, MD, on the Shocking Ibrutinib WithdrawalIn this episode of The HemOnc Pulse, Dr. Maddocks, Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University, charts the treatment evolution of mantle cell lymphoma (MCL) from frontline therapy to future directions. She also explains her initial shock, and subsequent bittersweet reaction to the withdrawal of ibrutinib.2023-11-1631 minASTCT TalksBeyond BCMA: Exploring Talquetamab in Myeloma TherapyIn this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Amrita Krishnan, MD. They delve into the use of GPRC5D as a target in myeloma therapy, specifically focusing on Talquetamab.
Dr. Krishnan shares insights from the MonumenTAL-1 trial, discussing the dosing schedules and response rates with GPRC5D-targeted therapy. They explore the unique toxicities associated with this treatment, such as cytokine release syndrome and skin and nail toxicities. The conversation also touches on the considerations for patients who have previously received BCMA-targeted therapies and the potential of...2023-11-1517 min
Oncology Data AdvisorVenetoclax for Multiple Myeloma in the Post-CANOVA Era: Rahul Banerjee, MD, FACP, and Andrew Yee, MDAt the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and Oncology Data Advisor Editorial Board Member, and Dr. Andrew Yee, Clinical Director for Multiple Myeloma at Massachusetts General Hospital, sat down to reflect on the surprising results of the trial and its implications for the current and future treatment of patients with t(11;14) multiple myeloma.2023-11-1520 minOncology Data AdvisorUpdates on Bispecific Antibodies in Multiple Myeloma From IMS 2023: Rahul Banerjee and Shonali MidhaAt this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.2023-11-0718 min
The HemOnc PulseJorge Cortes, MD, on Why Balance Is Key in CML TherapyDr. Cortes, who serves as Director of the Georgia Cancer Center at Augusta University, joins host Chadi Nabhan, MD, MBA, FACP, to chat about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Dr. Cortes discussed the evolution of tyrosine kinase inhibitors (TKIs) and the multiple generations of TKIs that are now available. Second-generation TKIs can lead to earlier and deeper responses than first-generation TKIs, he said, noting that this means patients receiving second-generation TKIs are more likely to be able to discontinue treatment.
“If I was diagnosed with CML, I would take a...2023-11-0223 minOncology Data AdvisorTwice Weekly, Biweekly, Somewhere in Between? Dosing in Myeloma: Rahul Banerjee and Gurbakhash KaurIn honor of Blood Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Dr. Rahul Banerjee sat down with Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas Southwestern Medical Center, to discuss updates and the advantages and disadvantages of different dosing schedules for treating multiple myeloma.2023-10-2317 min
The HemOnc PulseWhat Are the Top Questions in ALL?Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
In this episode, Dr. Jabbour, who is also an Associate Editor of Blood Cancers Today, the home of The HemOnc Pulse, discusses the most burning questions in acute lymphoblastic leukemia (ALL).2023-10-1924 min
The HemOnc PulseThe ABCs of MM Treatment According to Rafael Fonseca, MDDr. Fonseca offers his thoughts on the future of multiple myeloma (MM) treatment, the ongoing debate between chimeric antigen receptor (CAR)-T therapies and bispecifics, and the latest treatment news on bispecifics, including elranatamab, which had yet to be approved at the time of this recording.
The conversation also covers the role of measurable residual disease (MRD), the potential for bispecific therapies to democratize access to advanced treatments, and the intriguing prospect of CAR-T cells potentially replacing hematopoietic stem cell transplants in the first relapse—a scenario reminiscent of lymphoma care.
"I don't think it's far-fetched to think that there's go...2023-10-0529 min
The HemOnc PulseThe Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL TreatmentOn this episode of The HemOnc Pulse, guest Jonathan Friedberg, MD, MMSc, a hematologic oncologist at the University of Rochester Medicine – Wilmot Cancer Institute, chats with host Dr. Chadi Nabhan on the subtle but important shift in the treatment landscape of diffuse large B-cell lymphoma (DLBCL)in the post-POLARIX trial era.
The POLARIX trial, which was designed to improve upon the standard R-CHOP regimen for DLBCL treatment, investigated the potential of polatuzumab vedotin. The phase III trial ultimately resulted in the US Food and Drug Administration approving the treatment in previously untreated DLBCL, not otherwise specified, or high-grade B-cell lymphoma. Th...2023-09-1433 min
The HemOnc PulseDr. Garcia-Manero on the Data Behind the Luspatercept ApprovalGuillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, live at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss the phase III COMMANDS trial, the recent approval of luspatercept, and other developments in myelodysplastic syndromes (MDS) treatment and research.
Dr. Garcia-Manero spoke about the design of the phase III COMMANDS trial, which evaluated luspatercept versus epoetin alfa for the treatment of anemia in patients with lower-risk MDS who required red blood cell (RBC) transfusions but had not previously received an erythropoiesis-stimulating agent.
“The study is very interesting in...2023-09-1320 min
The HemOnc PulseMazyar Shadman, MD, MPH, Reports the Latest BTKi News in CLLDr. Shadman of the Fred Hutchinson Cancer Center in Seattle rounds up the latest news in chronic lymphocytic leukemia (CLL) from the summer conferences, including updates on novel Bruton tyrosine kinase inhibitor (BTKi) therapies in CLL.2023-08-2426 minASTCT TalksMonitoring After CAR-T Therapy for Multiple Myeloma: The APP PerspectiveIn this latest episode of ASTCT Talks, Rahul Banerjee interviews Josh Epworth, a lead nurse practitioner in the plasma cell disorders clinic at the Fred Hutchinson Cancer Center. They delve into the topic of monitoring after CAR-T therapy for multiple myeloma. Mr. Epworth shares insights from his experience in the outpatient setting, discussing issues like hypogammaglobulinemia, immune cell functionality, and infections that may arise after CAR-T treatment. They also touch on monitoring for cytomegalovirus (CMV) and other respiratory viruses, as well as the importance of developing close relationships with local healthcare providers to ensure patients receive timely care.
2023-08-1825 min
The HemOnc PulseBhavana Bhatnagar, MD, on the Molecular Revolution in AMLIn this episode of The HemOnc Pulse, Dr. Bhatnagar, an Associate Professor of Medicine at the West Virigina University Cancer Institute, reflects on how the molecular characterization of acute myeloid leukemia (AML) has evolved. She joins host Chadi Nabhan, MD, MBA, FACP, to discuss how this growing base of knowledge has impacted diagnosis, treatment, and classification.
“The most significant changes have come about as a result of improvements and refinements in the molecular characterization of AML,” Dr. Bhatnagar said.
Some of these changes include major updates in the World Health Organization and European LeukemiaNet systems.
The episode also highlights Dr. Bhat...2023-08-1025 min
The HemOnc PulseDo Venetoclax Combinations Trump Chemotherapy in Frontline CLL Treatment?Is there a venetoclax combination that reigns supreme in chronic lymphocytic leukemia (CLL)? Is venetoclax-based therapy the way to go in treating frontline CLL? Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, shares his thoughts on these questions and recent data published in the New England Journal of Medicine.2023-07-2724 min
The HemOnc PulseWhy Grzegorz Nowakowski, MD, Says There’s a ‘Revolution’ in LBCL TherapyDr. Nowakowski, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, talks about the revolution in treatment options in diffuse large B-cell lymphoma(DLBCL).
"The last couple of years, we've seen quite a revolution in the treatment of DLBCL," he said. "We have multiple approved therapies now, and more coming, so it's really a very rapidly changing field."
He also discusses the five-year follow-up data from the L-MIND study, which evaluated tafasitamab in combination with lenalidomide.2023-07-1325 min
The HemOnc PulseAn Expert’s Look into the World of Rare Blood CancersNaveen Pemmaraju, MD, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the rare, ultrarare, and forgotten blood cancers, including his lifelong work in blastic plasmacytoid dendritic cell neoplasm (BPDCN), in this episode of The HemOnc Pulse.2023-06-2925 min
The HemOnc PulseThe Logistics of CAR-T in Hematologic MalignanciesNavneet Majhail, MD, MS, the Physician in Chief at Sarah Cannon in Nashville, Tennessee, delves into the intricacies of chimeric antigen receptor (CAR) T-cell therapy, discussing the logistics and challenges involved with these therapies.
Dr. Majhail explores strategies to improve access to CAR-T therapy and he discusses the role of CAR-T amidst the availability of bispecific antibodies as treatments for blood cancers.2023-06-1525 min
The HemOnc PulseAbi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost EffectiveDrs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.2023-05-1832 minASTCT TalksTreating Cytopenias After CAR T-cell TherapyIn this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Tania Jain, MBBS. They dive into "How I Treat Cytopenias after CAR T-cell Therapy,” a paper published by Dr. Jain and co-authors (Timothy S. Olson, MD, PhD and Frederick Locke, MD) in Blood in February 2023. They discuss why cytopenias occur after CAR-T therapy, how to evaluate cytopenias after CAR-T therapy, who best to manage cytopenias after CAR-T and more.
About Dr. Rahul Banerjee, MD, FACP
Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical On...2023-05-0522 min
The HemOnc PulseSagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MMBlood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.2023-05-0422 min
The HemOnc PulseAlan Skarbnik, MD, Gives the Lowdown on Treating Patients with Follicular LymphomaAlan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma, the nuances involved in those decisions, and why bispecifics are here to stay, with host Chadi Nabhan, MD, MBA, FACP.2023-04-2032 minASTCT TalksBispecific Antibodies in Myeloma: The Who, What, When, and WhereIn this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Urvi A. Shah, MD, to discuss CAR-T vs bsAbs among academic audiences, bispecific antibodies (in particular commercially available teclistamab), future cycles of teclistamab, infections in published trials of bsAbs in myeloma and more.
About Dr. Rahul Banerjee, MD, FACP
Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical Oncology at the University of Washington and at the Fred Hutchinson Cancer Center. Prior to moving to Seattle, he completed his hematology/oncology fellowship and advanced...2023-04-1818 min
FUMO: Future Of Money Podcast58. Blockchain & Bonds: Reinventing Finance with Digital Ledger Technology | (with Rahul Banerjee, Founder & CEO Bondevalue)Are you curious about the potential impact of blockchain technology in the bond market?
Our next podcast episode features an interview with Rahul Banerjee, Founder & CEO of Bondevalue, who will discuss the use of digital ledger technology in finance, particularly in the bond market. He highlights how blockchain technology can help create a more efficient and trustworthy bond market by removing intermediaries like banks or financial institutions. Rahul also shares that he created an app called Bondevalue, which has since been rebranded as Bond Blocks, to reinvent the bond market using blockchain technology.
Don’t mi...2023-04-1048 min
The HemOnc PulseAmer Zeidan, MBBS, MHS, on the Evolution of AML Classification, TreatmentIn this episode of The HemOnc Pulse, Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates, the practical implications of testing for genetic alterations, and how patient characteristics inform his approach to treating AML, with host Chadi Nabhan, MD, MBA, FACP.2023-04-0626 min
The HemOnc PulseWhat Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?Swetha Kambhampati, MD, and Nikhil Thiruvengadam, MD, discuss the implications of their study investigating the cost-effectiveness of pola-R-CHP in previously untreated DLBCL.2023-03-2327 min
PoliticsarcaWhy Bengal CM Mamata Banerjee said that Rahul Gandhi is the biggest TRP of Bjp?
Why Bengal CM Mamata Banerjee said that Rahul Gandhi is the biggest TRP of Bjp?
#politicsarca #mamatabanerjee #rahulgandhi
---
Send in a voice message: https://podcasters.spotify.com/pod/show/politicsarca/message2023-03-2101 min
The HemOnc PulseGraham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin LymphomaIn the latest episode of The HemOnc Pulse, Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, a lymphoma specialist at Oxford Cancer and Haematology Centre, discusses the findings from the HoLISTIC Consortium, and what he thinks about checkpoint inhibitors upfront in the treatment of Hodgkin lymphoma.2023-03-0935 min
The HemOnc PulseWhat Keeps Michael Bishop, MD, Up at Night When it Comes to CAR-T?What is it about chimeric antigen receptor (CAR) T-cell therapies in hematologic oncology that keeps Michael Bishop, MD, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago, awake at night? In the latest episode of the podcast, Dr. Bishop discusses the matter and speaks about research that is identifying why CAR T-cell therapy doesn't always work.2023-02-2336 min
The HemOnc PulseLaurie H. Sehn, MD, MPH, on the Game-Changing Bispecifics in Follicular LymphomaIn the latest episode of The HemOnc Pulse, Laurie H. Sehn, MD, MPH, Chair of the Lymphoma Tumour Group at the BC Cancer Centre for Lymphoid Cancer, talks with host Chadi Nabhan, MD, MBA, FACP, about which bispecific antibodies will change the game in follicular lymphoma treatment. Dr. Sehn also explains why the TRIANGLE study is anticipated to be practice-changing and how it may make upfront transplant obsolete in MCL.2023-02-0937 min
The HemOnc PulseSanam Loghavi, MD, Tells Us Why 2022 was a Major Year for MDSSanam Loghavi, MD, stops by The HemOnc Pulse and chats with host Chadi Nabhan, MD, MBA, FACP, about why she thinks 2022 was a major year for MDS in this latest episode of the podcast. With the unveiling of the two new MDS classification systems in the past year, Dr. Loghavi breaks down the classification models and what it means for the specialty.2023-01-2639 min
The HemOnc PulseElizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be IgnoredIn the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia (CLL) abstracts from ASH 2022 cannot be ignored, the latest news in Richter’s transformation, and why she is moving away from ibrutinib in her own clinical practice.2023-01-1236 min
The HemOnc PulseRuben Mesa, MD, Discusses MPN Updates at ASH 2022 and the Evolution of the DiseaseRuben Mesa, MD, President and Executive Director of the Atrium Health cancer service line (formerly the Executive Director of Mays Cancer Center), discusses his long career in myeloproliferative neoplasms (MPNs), the evolution of the disease, and what abstracts caught his attention at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.2022-12-2930 min
The HemOnc PulseDrs. Hagop Kantarjian and Elias Jabbour Discuss Important AML, ALL Updates From ASH 2022In the inaugural episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Hagop Kantarjian, MD, and Elias Jabbour, MD, both of the Department of Leukemia at the University of Texas MD Anderson Cancer Center. The trio cover high-impact studies, novel treatment strategies, and controversial standard-of-care approaches for AML as well as ALL that were presented at the 2022 American Society of Hematology Annual Meeting & Exposition.2022-12-1444 min
Oncology Data AdvisorUnderstanding Clonal Hematopoiesis With Rahul Banerjee, Jeremy Meier, and Samuel RubinsteinDr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.2022-11-1425 min
Oncology Data AdvisorBlood Cancer Awareness Month: Exploring Patient-Reported Outcomes: Rahul Banerjee and Ajay MajorRecently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.2022-10-0731 min
The DeshBhakt With Akash BanerjeeRahul Gandhi: Modi’s Biggest Weapon? | 15 Reasons WHY | Akash BanerjeeRahul Gandhi was in the news this week - again - this time because he was spotted in a Pub in Nepal. The Opposition had a field day - claiming that Rahul was there with the Chinese Ambassador. While none of that was true - what is sadly true is that Rahul continues to be the gift for the Govt and instead of counterbalancing the Govt - he's helping with the rise of an authoritarian government. Here's 14 reasons why Rahul is Modi's best and biggest weapon to stay in power.
The Congress IT cell c...2022-05-0920 minOncology Data AdvisorConsidering VTE Risk Factors and Prophylaxis in Myeloma: Rajshekhar Chakraborty and Rahul BanerjeeIn this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Rajshekhar Chakraborty about risk factors for the development of venous thromboembolism (VTE) in patients with multiple myeloma and the considerations for thromboprophylaxis during their treatment.2022-04-1119 minOncology Data AdvisorCan Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul BanerjeeIn honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma.2022-04-0623 minOncology Data AdvisorAdvocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul BanerjeeIn this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myeloma.2022-03-2424 minOncology Data AdvisorCan Digital Life Coaching Improve Quality of Life in Transplant? Rahul Banerjee and Kelly BrassilDr. Rahul Banerjee and Dr. Kelly Brassil discuss the design of an ongoing phase 2 trial investigating digital life coaching and its implications for improving the quality of life of patients undergoing ASCT for multiple myeloma.2022-02-1727 min
Plenary Session - inactive due to federal service4.06 CAR-T, Oncology RCTs, Social Media, Myeloma, and Career Decisions with Dr. Rahul BanerjeeWe sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions.
What Oncologists Can Learn From COVID-19: doi.org/10.1038/s41571-020-00448-y
Are Observational, Real-World Studies Suitable: doi.org/10.1001/jamanetworkopen.2020.12119
Back us on Patreon! www.patreon.com/plenarysession
Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew2021-07-081h 31Plenary Session - inactive due to federal service4.06 CAR-T, Oncology RCTs, Social Media, Myeloma, and Career Decisions with Dr. Rahul BanerjeeWe sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions.
What Oncologists Can Learn From COVID-19: doi.org/10.1038/s41571-020-00448-y
Are Observational, Real-World Studies Suitable: doi.org/10.1001/jamanetworkopen.2020.12119
Back us on Patreon! www.patreon.com/plenarysession
Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew2021-07-081h 31
Sales Spin5: Use memes to booking more meetings - Avirup BanerjeeIf you are struggling to get meetings, adding memes to your outbound may do the trick. Watch the episode to find out why it's important and how can you do it?
If you haven't followed our Instagram, comment below and we will send you memes :)
If you have followed us already, tell us your experience using memes in prospecting.
Connect with me on Linkedin
Follow Sales Spin on Linkedin
Follow us on Instagram for a daily dose of Sales Memes
---
Send in a voice message: https://podcasters.s...2021-06-3023 min
Where Dreams Come FromRahul Banerjee (English)Trained as an engineer at the Indian Institutes of Technology or IIT, my guest Rahul Banerjee gave up the securities of an Indian middle class life to serve his country. He threw his lot behind the indigenous Bhil tribal folk in central India. Along the way, he has completed a PhD, become an Ashoka Fellow and completed numerous research projects for organizations internationally. But the central focus, as Banerjee explains, has been a lifelong process of unlearning and then organizing to secure constitutional rights for the poorest of the poor in India. This conversation is a snapshot of that...2021-05-1924 min
ETV Bharat English NewsEnglish News May 05, 2021 9pm|ETV Bharat English Rahul Gandhi|S Jaishankar|Mamata Banerjee|Congress MP Rahul Gandhi asked why there is no transparency regarding the medical supplies sent from across the world. External Affairs Minister S Jaishankar said that India's relationship with China is going through a "very difficult phase" West Bengal Chief Minister Mamata Banerjee wrote to Prime Minister Narendra Modi requesting him to ensure adequate supply of COVID vaccines, medical oxygen, and drugs like Remdesivir
For more live news download Etv Bharat
Download ETV Bharat on
App store – https://apps.apple.com/in/app/etv-bharat/id1453416186
Play Store – https://play.google.com/store/apps/details?id=com.etvbharat.android
Or watch us l...2021-05-051h 06ETV Bharat English NewsEnglish News May 03, 2021 6pm|ETV Bharat English Mamata Banerjee Oath|Rahul Gandhi|NEET|TMC leader Partha Chatterjee informed that West Bengal Chief Minister Mamata Banerjee will take oath for the third time on 5 May.Congress leader Rahul Gandhi accused the central government of being "policy paralysed" and said that it cannot secure victory over coronavirus.The NEET Exam 2021 has been postponed for at least 4 months.
For more live news download Etv Bharat
Download ETV Bharat on
App store – https://apps.apple.com/in/app/etv-bharat/id1453416186
Play Store – https://play.google.com/store/apps/details?id=com.etvbharat.android
Or watch us live on – www.etvbharat.com
ETV Bharat is a Division of Ushoda...2021-05-031h 39
The DeshBhakt With Akash BanerjeeHow Congress Lost Bihar (and a whole lot more under Rahul) | The Deshbhakt with Akash BanerjeeThe Congress had not won a single assembly election on its own steam in the last 2 years - the latest Bihar debacle only adds to the list of failures and destroys changes of a Rahul comeback any time soon as Party President .... so the congress will limp though another few months with 5 assembly elections are due.
To add insult to the Bihar injury - not even Former US President Obama added that Rahul Gandhi does not have the drive to make it in politics - given the track record - what does Rahul do now?
...2020-11-1310 min
The DeshBhakt With Akash Banerjee"Congress is Jurassic" - Sanjay Jha after Sachin Pilot is sacked | 10 Questions with Akash BanerjeeJust days after Sanjay Jha was given the boot as National Spokesperson - the Congress saw another exit - this time it was Sachin Pilot who was stripped off his PCC post and that of the Dy CM of Rajasthan. But why is the Congress leadership refusing to listen / learn with the time??? The DeshBhakt asks 10 pointed questions to the now sacked National Spokesperson of the Congress and tries to find out what is ailing the grand old party.
10 QUESTIONS TO SANJAY JHA -
00:00 - Introduction / Why was Sanjay Jha sacked as Nat...2020-07-1440 min
SportZindagiDaily Sport Update-10th July 2020West Indies dominated the day two of the first Cricket test match with England. They were 57 for 1 at the stumps in response of England's 204 in their first innings. West Indian captain Jason Holder created a record by taking 6 wickets for 42 runs. It was not only his best performance ever, but also by any West Indian captain against England. BCCI has asked its CEO Rahul Johri to step down & Sports Ministry has asked Hockey India's President Mushtaq Ahmad to step down immediately.2020-07-1007 min